

New Products - Zarzio

Zarzio (**filgrastim (rbe)**) is a recombinant Human Granulocyte Colony Stimulating Factor (rmetHuG-CSF) derived from *E. coli*. Zarzio is indicated in the reduction of neutropenia duration, clinical sequelae after induction/ consolidation chemotherapy in AML; following autologous or allogeneic bone marrow transplant. It is also indicated in the mobilisation of peripheral blood progenitor cells (PBPC) following myelosuppressive chemotherapy (autologous) or in normal donors (allogeneic); infection incidence reduction during myelosuppressive chemotherapy in nonmyeloid malignancy; severe chronic neutropenia (SCN); and in the maintenance of adequate neutrophils during antiretroviral/ myelosuppressive HIV therapy. Zarzio is contraindicated in patients with known hypersensitivity to *E coli* derived products. Zarzio is available as a 300 microgram per 0.5 mL and 480 microgram per 0.5 mL prefilled syringe.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.